Skip to main content
Home
Toggle menu

Give Now

  • For Patients
  • School Of Medicine
  • About
    • Leadership
    • Department Directory
    • News
    • Events
    • Annual Report
    • Nashville
  • Divisions
    • Allergy, Pulmonary and Critical Care Medicine
    • Cardiovascular Medicine
    • Diabetes, Endocrinology and Metabolism
    • Epidemiology
    • Gastroenterology, Hepatology and Nutrition
    • General Internal Medicine and Public Health
    • Genetic Medicine and Clinical Pharmacology
    • Geriatric Medicine
    • Hematology and Oncology
    • Infectious Diseases
    • Nephrology and Hypertension
    • Rheumatology and Immunology
  • Education
    • Overview
    • Internal Medicine Residency Program
    • Physician-Scientist Training Program
    • Internal Medicine-Pediatrics Residency Program
    • Fellowship Programs
    • EXCellence In TEaching Pathway
    • Physician-Scientist Doctoral Program
    • Medical Students
    • Alumni
    • Medicine Grand Rounds
  • Research
    • Overview
    • Clinical Trials
    • Publications
    • Research Centers and Labs
  • Faculty
    • Open Faculty Positions
    • Professional Development
  • Clinical Initiatives
    • Digital Health
    • Physician Builder Program

User Detail

David Haas, MD

Professor of Medicine

Division of Infectious Diseases
David Haas
Professional Bio
David Haas, MD, is Professor of Medicine in the Division of Infectious Diseases within the Department of Medicine at Vanderbilt University Medical Center. He is also a Professor of Pharmacology, Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine, and Adjunct Professor of Internal Medicine at Meharry Medical College. He is also a board-certified infectious diseases specialist. As an accomplished HIV clinical trialist and leader in human pharmacogenomic research relevant to HIV infection and its therapy, Dr. Haas has led the design and implementation of many HIV clinical trials since the early 1990s. In recent years his work has expanded to include pharmacogenomics of anti-tuberculosis therapy. He established and has led the AIDS Clinical Trials Group (ACTG) Clinical Research Site at Vanderbilt since its inception. He has led the ACTG's pharmacogenomics program since 2000, and championed the establishment of the ACTG's Human DNA Repository. His work with the ACTG led to the seminal observation that a frequent CYP2B6 polymorphism predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent. He is co-PI of a substantial, multidisciplinary R01 entitled "Pharmacogenomics of HIV Therapy." Dr. Haas is highly engaged in multidisciplinary research with an emphasis on the importance of human genomics for antiretroviral and anti-tuberculosis drug disposition, efficacy, and toxicity. He is also associate director of the Tennessee Center for AIDS Research.
Relevant Links
Provider Profile
Publications
View Publications

Education

MD - Vanderbilt University, 1983

Residency - Medicine - Vanderbilt University, 1987

Fellowship - Infectious Diseases - Vanderbilt University, 1991

Contact

Email 
Kimryn.Rathmell@Vumc.Org 
Address 
777 Preston Research Building 
2220 Pierce Ave 
Nashville, TN 37232-6307

Submitted by admin on Thu, 06/01/2023 - 04:28

1161 21st Ave S
Nashville, TN 37232

(615) 322-5000

Quick Links

  • Home
  • About
  • Divisions
  • Education
  • Research
  • Faculty
  • Intranet

Support Our Work

Start a fundraiser or donate to the Department of Medicine.

Give Now

Vanderbilt Health is committed to fostering an environment where everyone has the chance to thrive and is committed to the principles of equal opportunity. EOE/Vets/Disabled.

Copyright © Vanderbilt University Medical Center

sfy39587stp18